Valemetostat tosylate not checked

Daiichi Sankyo · DS-3201b · DS-3201

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
7 active
10 in total · 6 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Oral administration of valemetostat tosylate at a dose of 200 mg once daily starting at Cycle 1, Day 1 (continuous for 28-day cycles), until disease progression or unacceptable toxicity”In the company’s words, NCT04703192 on ClinicalTrials.gov
Tested for
Relapsed/Refractory Peripheral T-Cell Lymphoma, Adult T Cell Leukemia/Lymphoma, Non-small Cell Lung Cancer, Lung Cancer, Lymphoma, Malignant, Non-hodgkin Lymphoma, Metastatic Castration-resistant Prostate Cancer, Advanced Solid Tumor
Main trialPhase 2
“This study will characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell lymphoma, including relapsed/refractory adult T-cell leukemia/lymphoma.”In the company’s words, NCT04703192 on ClinicalTrials.gov
Other names
DS-3201b · Valemetostat · DS-3201

Other drugs for Relapsed/Refractory Peripheral T-Cell Lymphoma

All 34 drugs for Relapsed/Refractory Peripheral T-Cell Lymphoma

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials10

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting 10 May 2023 Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
Phase 1/2Active, not recruiting 30 Mar 2028 A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
Phase 1Active, not recruiting 31 Dec 2022 DS-3201b in Participants With Lymphomas
Phase 1Recruiting 31 Jan 2028 A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
Phase 1Active, not recruiting 1 Nov 2028 A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
Phase 2Completed 24 Apr 2021 Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma
Phase 1Completed 23 Feb 2021 Study of Single-dose DS-3201b in Participants With Hepatic Impairment
Phase 1Terminated 9 Mar 2021 DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)
Phase 2Authorised not given VALYM - A phase II open-label study evaluating valemetostat tosylate as a single agent in patients with relapse/refractory B-cell lymphoma
Phase 2Authorised not given An open label phase II platform modular study exploring the efficacy and safety of the Valemetostat (EZH1/2 inhibitor) in patients with selected solid tumors (EZHiSWITCH)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Valemetostat tosylate

Following is part of Solo: you see every change to Valemetostat tosylate the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in